Glioblastoma brain cancer, a really tough type of brain tumor, presents some serious challenges for doctors and patients. It's known for being aggressive and hard to treat, often coming back even after treatment.
This article looks into why glioblastoma is so tricky, what makes it tick on a cellular level, and the new ideas researchers are exploring to fight it.
Top Points
Glioblastoma is a fast-growing brain cancer that's difficult to treat because it spreads easily and is resistant to standard therapies.
Tumor stem cells play a big role in glioblastoma coming back after treatment.
Glioblastoma can hide from the body's immune system, making it harder for the body to fight it off.
Treatments like surgery, radiation, and chemotherapy are standard, but the blood-brain barrier makes it hard for drugs to reach the tumor.
New methods are being developed to get treatments past the blood-brain barrier, like using focused ultrasound and nanoparticles.
Researchers are looking into new treatments such as immunotherapy, oncolytic viruses, and targeting the tumor's metabolism.
The Unique Biological Challenges of Glioblastoma
Why Is Glioblastoma So Resistant to Standard Therapy Beyond Its Grade IV Classification?
Glioblastoma, often referred to as GBM, is a particularly aggressive form of brain cancer. It starts in star-shaped cells called astrocytes, which are part of the brain's supportive tissue.
While classified as a Grade IV tumor, its resistance to treatment goes beyond just its grade. One major hurdle is the tumor's infiltrative nature.
As glioblastoma grows, it sends out tiny, finger-like projections that spread into the surrounding healthy brain tissue. This makes it incredibly difficult, if not impossible, for surgeons to remove every single cancer cell. Even when a surgery appears to remove the entire tumor, microscopic remnants can remain, setting the stage for recurrence.
Another significant challenge is the sheer diversity within a single glioblastoma tumor. These tumors are not made of just one type of cell; they contain many different kinds of cells, each with its own characteristics.
This cellular heterogeneity means that a treatment, like a chemotherapy drug, might be effective against some cells but completely ineffective against others. This makes finding a single treatment that can tackle the entire tumor population a complex task.
Furthermore, glioblastomas often lack specific genetic mutations, such as those in the IDH gene, which are found in slower-growing brain tumors that tend to respond better to therapy. The absence of these mutations contributes to glioblastoma's aggressive behavior and poor response to conventional treatments.
How Do Glioblastoma Stem Cells (GSCs) Specifically Contribute to Tumor Recurrence?
One of the key reasons glioblastoma tumors often come back after treatment is the presence of glioblastoma stem cells, or GSCs.
These are a small population of cells within the tumor that have properties similar to normal stem cells. They are thought to be responsible for initiating tumor growth and, importantly, for the tumor's ability to regrow after therapy.
GSCs are often more resistant to chemotherapy and radiation than the bulk of the tumor cells. This means that while standard treatments might kill off most of the cancer cells, the GSCs can survive and then start the process of tumor regrowth.
This survival and regenerative capacity make GSCs a major focus for neuroscience researchers trying to find ways to prevent glioblastoma from recurring.
How Do Glioblastoma Tumors Successfully Evade the Body's Immune System?
Glioblastoma tumors are also adept at hiding from or disabling the body's own immune system, which is designed to fight off foreign invaders like cancer cells.
One way they do this is by creating an environment around the tumor that suppresses immune responses. They can release certain molecules that tell immune cells to stand down or even turn them into cells that help the tumor grow.
Additionally, glioblastoma cells can express proteins on their surface that act like a shield, preventing immune cells from recognizing and attacking them.
How Do Researchers Decode the Molecular Landscape of Glioblastoma?
Glioblastoma is a complex brain cancer, and understanding its inner workings is key to finding better ways to treat it. It's not just one disease; it's more like a collection of different types, each with its own molecular fingerprint.
This molecular makeup significantly influences how the cancer behaves and how it might respond to treatment.
What Is the Difference Between IDH-Wildtype and IDH-Mutant Diseases?
One of the most important distinctions in glioblastoma classification is the status of the IDH gene.
This gene plays a role in cell metabolism. When the IDH gene is mutated, it often leads to a slower-growing tumor that tends to respond better to certain treatments.
Conversely, IDH-wildtype glioblastomas, which lack these mutations, are generally more aggressive and harder to treat. This genetic difference means that IDH-wildtype and IDH-mutant glioblastomas are often considered distinct diseases requiring different therapeutic strategies.
How Does MGMT Promoter Methylation Impact Glioblastoma Treatment Efficacy?
Another critical molecular marker is the methylation status of the MGMT gene promoter. The MGMT protein helps repair DNA damage, including damage caused by chemotherapy drugs like temozolomide.
When the promoter region of the MGMT gene is methylated, it effectively silences the gene, reducing the production of the MGMT protein. This silencing makes the tumor cells more vulnerable to chemotherapy, as their DNA repair mechanisms are impaired.
Therefore, patients whose tumors have methylated MGMT promoters often have a better response to temozolomide treatment compared to those with unmethylated MGMT promoters. Testing for MGMT promoter methylation is a standard part of diagnosing and planning treatment for glioblastoma.
How Can Medicine Break Through and Overcome the Blood-Brain Barrier?
What Innovative Drug Delivery Systems Are Currently in Development?
The blood-brain barrier (BBB) is a protective shield that keeps the brain safe from harmful substances in the bloodstream. While this is good for general brain health, it makes treating brain cancers like glioblastoma incredibly difficult.
Most cancer drugs simply can't get past this barrier in sufficient amounts to be effective. Researchers are exploring several new ways to get treatments where they need to go.
Can Focused Ultrasound Be Used to Temporarily Open the Blood-Brain Barrier?
One promising approach involves using focused ultrasound. This technology uses sound waves to create tiny, temporary openings in the BBB.
Think of it like briefly unlocking a door. When the barrier is temporarily opened in a specific area, drugs that normally wouldn't get through can then enter the brain tissue around the tumor.
This method is being studied to see how it can improve the delivery of chemotherapy drugs and other therapies directly to the glioblastoma site, potentially increasing their impact while minimizing side effects elsewhere in the body.
How Does Nanoparticle Technology Deliver Therapeutics Directly to the Brain?
Another area of active research is the use of nanoparticles. These are incredibly small particles, much smaller than cells, that can be engineered to carry medication.
Because of their tiny size, nanoparticles can sometimes slip through the BBB more easily than larger drug molecules. Scientists are designing these nanoparticles to specifically target cancer cells, so they release their drug payload right where it's needed.
This targeted approach aims to make treatments more potent against the tumor and reduce damage to healthy brain tissue. The development of these advanced delivery systems is a key step in making glioblastoma treatments more effective.
The Next Wave of Glioblastoma Therapies
Which Immunotherapy Approaches Use Vaccines and CAR-T Cells to Fight Glioblastoma?
Treatments for glioblastoma are always evolving, and a lot of current research is looking into ways to get the body's own immune system to fight the cancer.
This is called immunotherapy. One idea is to use checkpoint inhibitors. These are drugs that essentially take the brakes off immune cells, allowing them to attack cancer cells more effectively.
Another approach involves creating vaccines specifically designed to train the immune system to recognize and destroy glioblastoma cells.
Researchers are also exploring CAR-T cell therapy, where a patient's T-cells (a type of immune cell) are collected, genetically modified in a lab to better target cancer, and then put back into the patient. The goal with all these methods is to create a more lasting immune response against the tumor.
How Does Oncolytic Virus Therapy Harness Viruses to Kill Cancer Cells?
Oncolytic virus therapy uses viruses that are naturally good at infecting and killing cancer cells, or viruses that have been modified to do so. These viruses are introduced into the tumor, where they replicate inside the cancer cells, causing them to burst and die.
As a bonus, this process can also trigger an immune response against the remaining cancer cells. It's a bit like using a Trojan horse strategy to attack the tumor from within. Scientists are working to make these viruses more effective and safer for patients.
What New Targets Are Found by Exploring Metabolic Pathways and Cellular Signalling?
Glioblastoma cells have unique ways of getting the energy and signals they need to grow and survive. Researchers are investigating these metabolic pathways and signalling routes to find new vulnerabilities.
For example, some glioblastoma cells rely heavily on certain nutrients or have overactive growth signals. By identifying these specific dependencies, new drugs can be developed to block these pathways, starving the tumor or disrupting its growth signals.
This targeted approach aims to be more precise than traditional treatments, potentially leading to fewer side effects.
How Can Researchers Harness Bioelectricity for Glioblastoma Treatment?
How Do Tumor-Treating Fields (TTFields) Use Electrical Fields to Disrupt Cancer Cells?
As researchers look beyond traditional chemical and radiological approaches, bioelectric therapies have emerged as a significant frontier in glioblastoma care.
The most prominent of these is Tumor-Treating Fields (TTFields), an FDA-approved intervention clinically available as a wearable device. Unlike monitoring technologies, this therapy actively targets the tumor by delivering continuous, low-intensity, alternating electrical fields directly to the brain via an array of adhesive pads placed on the scalp.
Because glioblastoma cells divide at an aggressive rate, these specific electrical frequencies are designed to interfere with the cellular machinery required for mitosis, effectively disrupting the cancer's ability to replicate and inducing cellular death.
TTFields therapy is not a standalone cure; rather, it is integrated into the standard of care alongside maintenance chemotherapy following initial surgery and radiation.
What Is the Potential for Advanced EEG to Function as a Biomarker in Research?
While bioelectric therapies deliver external fields to fight the tumor, researchers are also utilizing the brain's intrinsic electrical signals to better understand the brain disease.
In glioblastoma clinical trials, advanced quantitative electroencephalography (qEEG) is increasingly being explored as a functional biomarker.
Traditional structural imaging, such as an MRI, is indispensable for tracking the physical dimensions of a tumor, but it cannot always capture the nuanced, real-time cognitive impacts of the cancer or the neurotoxicity of experimental treatments.
By continuously mapping the brain's electrical activity, qEEG provides an objective, measurable readout of a patient's underlying neurocognitive network function. This allows clinical investigators to track how the brain's functional environment responds to novel therapies, providing a vital layer of data that complements structural imaging.
Ultimately, utilizing qEEG helps researchers evaluate whether an emerging treatment is successfully preserving the patient's neurological integrity and overall quality of life alongside its anti-tumor effects.
What Is the Future for the Evolving Landscape of Glioblastoma Research?
Glioblastoma remains a formidable challenge in neuro-oncology, characterized by its aggressive nature and limited treatment options. Despite advances in surgery, radiation, and chemotherapy, the prognosis for patients has seen only modest improvements over the past decades.
The disease's ability to infiltrate brain tissue and its inherent cellular heterogeneity make complete eradication difficult, often leading to recurrence. However, ongoing research is shedding light on the complex biology of glioblastoma, identifying potential new therapeutic targets such as the prion protein and its interaction with tumor stem cells.
These discoveries, while still in early stages, offer hope for developing more effective strategies to combat this devastating cancer. Continued investment in clinical trials and a deeper understanding of glioblastoma's molecular underpinnings are vital for improving patient outcomes and ultimately finding a cure.
References
Cohen, A. L., Holmen, S. L., & Colman, H. (2013). IDH1 and IDH2 mutations in gliomas. Current neurology and neuroscience reports, 13(5), 345. https://doi.org/10.1007/s11910-013-0345-4
Koshrovski-Michael, S., Ajamil, D. R., Dey, P., Kleiner, R., Tevet, S., Epshtein, Y., ... & Satchi-Fainaro, R. (2024). Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin–expressing cancers. Science advances, 10(50), eadr4762. https://doi.org/10.1126/sciadv.adr4762
Ferber, S., Tiram, G., Sousa-Herves, A., Eldar-Boock, A., Krivitsky, A., Scomparin, A., ... & Satchi-Fainaro, R. (2017). Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome. Elife, 6, e25281. https://doi.org/10.7554/eLife.25281
Carvalho, H. M., Fidalgo, T. A., Acúrcio, R. C., Matos, A. I., Satchi‐Fainaro, R., & Florindo, H. F. (2024). Better, Faster, Stronger: Accelerating mRNA‐Based Immunotherapies With Nanocarriers. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 16(6), e2017. https://doi.org/10.1002/wnan.2017
Longobardi, G., Miari, A., Liubomirski, Y., Buderovsky, E., Levin, A. G., & Satchi-Fainaro, R. (2026). Abstract LB329: Overcoming the blood-brain barrier to potentiate GD2-CAR T therapy using P-selectin-targeted nanomedicine. Cancer Research, 86(8_Supplement), LB329-LB329. https://doi.org/10.1158/1538-7445.AM2026-LB329
Hamad, A., Yusubalieva, G. M., Baklaushev, V. P., Chumakov, P. M., & Lipatova, A. V. (2023). Recent developments in glioblastoma therapy: oncolytic viruses and emerging future strategies. Viruses, 15(2), 547. https://doi.org/10.3390/v15020547
American Association for Cancer Research. (2026, April 1). FDA approvals in oncology: January-March 2026. AACR Cancer Research Catalyst. https://www.aacr.org/blog/2026/04/01/fda-approvals-in-oncology-january-march-2026/
de Ruiter, M. A., Meeteren, A. Y. S. V., van Mourik, R., Janssen, T. W., Greidanus, J. E., Oosterlaan, J., & Grootenhuis, M. A. (2012). Neurofeedback to improve neurocognitive functioning of children treated for a brain tumor: design of a randomized controlled double-blind trial. BMC cancer, 12(1), 581. https://doi.org/10.1186/1471-2407-12-581
Frequently Asked Questions
What exactly is glioblastoma?
Glioblastoma is a type of brain cancer that starts in the brain's star-shaped cells, called astrocytes. These cells normally help support and protect the brain. When they become cancerous, they grow and spread very quickly, making glioblastoma a very serious condition.
Why is glioblastoma so hard to treat?
Glioblastoma is tough to treat for a few reasons. The cancer cells can spread out like tiny roots into the brain, making it almost impossible to remove them all with surgery. Also, the cancer is made up of many different kinds of cells, so a treatment that works on one type might not work on others. It's also very good at hiding from the body's own defense system.
What are the common symptoms of glioblastoma?
Symptoms can vary depending on where the tumor is in the brain. Some common signs include bad headaches that don't go away, seizures, and changes in personality or behavior. You might also notice problems with speech or movement.
How do doctors find out if someone has glioblastoma?
Doctors usually diagnose glioblastoma by taking a small piece of the suspicious tissue and looking at it under a microscope. They also do special tests to check for changes in the cancer cells' genes. Brain scans like MRIs are also used to see the tumor.
What are the main treatments for glioblastoma?
The main treatments usually involve a combination of surgery to remove as much of the tumor as possible, radiation therapy to kill cancer cells, and chemotherapy, which uses drugs to fight the cancer. Sometimes, special devices that create electrical fields are also used.
What are glioblastoma stem cells?
These are special cancer cells within the tumor that are like the 'seeds' of the cancer. They can stay quiet for a while but then start growing and causing the tumor to come back, even after treatment. They are very good at renewing themselves and can create new tumor cells.
What is the blood-brain barrier and why is it a challenge?
The blood-brain barrier is a protective shield that keeps most substances in the bloodstream from reaching the brain. While this protects the brain from harmful things, it also makes it very difficult for cancer-fighting drugs to get into the brain to treat tumors like glioblastoma.
Are there new ways to get medicine past the blood-brain barrier?
Yes, scientists are developing new methods. These include using tiny particles called nanoparticles to carry drugs, using focused ultrasound waves to temporarily open the barrier, and creating special drug delivery systems designed specifically for the brain.
What is immunotherapy for glioblastoma?
Immunotherapy is a type of treatment that helps the patient's own immune system fight the cancer. For glioblastoma, this can involve using special drugs, creating vaccines to train the immune system, or using modified immune cells (like CAR-T cells) to attack the tumor.
Emotiv is a neurotechnology leader helping advance neuroscience research through accessible EEG and brain data tools.
Emotiv
